cell

Cell Impact has been awarded gold medal by EcoVadis

KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ -- Last year, Cell Impact was awarded silver by EcoVadis. This year, the company has…

2 weeks ago

Hyundai Motor Group and Pyeongtaek City Collaborate to Advance CarbonNeutral Hydrogen Port Development

Hyundai Motor Group signs a multilateral MoU with Pyeongtaek City and key stakeholders to develop carbon-neutral hydrogen port initiativesKia and…

2 weeks ago

Cell Impact and thyssenkrupp Automation Engineering have entered a cooperation agreement

KARLSKOGA, Sweden, Nov. 6, 2025 /PRNewswire/ -- Cell Impact and thyssenkrupp Automation Engineering have entered a Strategic Cooperation Agreement for Joint Market…

2 weeks ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic…

3 weeks ago

Cellectis to Report Third Quarter Financial Results on November 7, 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…

3 weeks ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered…

1 month ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its…

1 month ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

1 month ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

1 month ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…

1 month ago